跳转至内容
Merck

SML3361

Sigma-Aldrich

Imepitoin

≥98% (HPLC)

别名:

1-(4-Chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one, 1-(4-Chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one, AWD 131-138, AWD131-138, ELB138

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H14ClN3O2
分子量:
279.72
MDL號碼:
分類程式碼代碼:
51111800
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

O=C1N=C(CN1C2=CC=C(C=C2)Cl)N3CCOCC3

InChI

1S/C13H14ClN3O2/c14-10-1-3-11(4-2-10)17-9-12(15-13(17)18)16-5-7-19-8-6-16/h1-4H,5-9H2

InChI 密鑰

IQHYCZKIFIHTAI-UHFFFAOYSA-N

生化/生理作用

Imepitoin (AWD 131-138; ELB 138) is a g-aminobutyric acid A (GABAA) receptor partial positive allosteric modulator (PAM) that targets the benzodiazepine (BZD)-binding site at the α/γ2-interface. Imepitoin enhances GABA current (% response/[GABA] alone in µM/receptor complex = 320/3/α1β2γ2, 310/25/α1β3γ2, 460/8/α2β2γ2, 590/12/α3β2γ2 and 290/3/α5β2γ2 using Xenopus oocytes expressing respective rat receptor complex) with ~2% the potency and 17-27% the efficacy of diazepam toward α1β2γ2. Imepitoin exhibits in vivo therapeutic efficacy in animal models of seizure and epilepsy.

象形圖

Health hazard

訊號詞

Warning

危險聲明

危險分類

Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

E Sigel et al.
Neuroscience letters, 245(2), 85-88 (1998-05-30)
Recombinant gamma-aminobutyric acid A (GABA(A)) receptors of the subunit compositions alpha1beta2gamma2, alpha1beta3gamma2, alpha2beta2gamma2, alpha3beta2gamma2 and alpha5beta2gamma2 were expressed in Xenopus oocytes in a functionally active form. At all subunit combinations, AWD 131-138 dose-dependently stimulated GABA currents. At 10 microM AWD
Chris Rundfeldt et al.
CNS drugs, 28(1), 29-43 (2013-12-21)
Although benzodiazepines (BZDs) offer a wide spectrum of antiepileptic activity against diverse types of epileptic seizures, their use in the treatment of epilepsy is limited because of adverse effects, loss of efficacy (tolerance), and development of physical and psychological dependence.
Wolfgang Löscher et al.
Pharmacological research, 77, 39-46 (2013-09-24)
Recently, the imidazolinone derivative imepitoin has been approved for treatment of canine epilepsy. Imepitoin acts as a low-affinity partial agonist at the benzodiazepine (BZD) site of the GABAA receptor and is the first compound with such mechanism that has been

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门